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a b s t r a c t
Background: Cerebrovascular events that occur during structural and interventional procedures are a well known
risk which is associated with increased mortality. The FDA has approved the use of the Sentinel device in TAVR.
Hereby we report on our experience on the safety and efﬁcacy of using Sentinel in a patient population undergoing non-TAVR transcatheter procedures.
Methods: Retrospective analysis of a single center experience with using the Sentinel device for non-TAVR transcatheter procedures.
Results: We identiﬁed 33 patients (average age was 73.8 years, 36.7% females, and 30% with history of a prior
stroke) felt to be at high risk for cerebroembolic events that underwent Sentinel device placement. Sentinel
placement was successful in all patients. Examples of high risk features included high atheroma burden in the
aortic arch, left sided valve vegetations, intra-cardiac thrombi and severe left sided valve calciﬁcations/thrombi.
No patients developed periprocedural stroke or vascular complications.
Conclusion: Overall, the use of Sentinel for non-TAVR indications appears feasible and safe. The use of cerebral
protection devices should be studied further in non-TAVR patients to establish its role and its beneﬁts, especially
with expanding the number of non-TAVR transcatheter interventions.
© 2021 Published by Elsevier Inc.

1. Introduction
Catheter-based cardiovascular interventions continue to evolve as
new devices continue to expand the capabilities of interventional cardiologists and to improve patient safety. The potential for embolization of
atheroma, vegetation of thrombus during catheter based cardiac interventions has long been recognized. Periprocedural stroke during transcatheter intervention is a rare but serious complication; it is associated
with high mortality and impaired quality of life [1].
Over the past decade, transcatheter aortic valve replacement (TAVR)
had emerged as a rapidly growing therapy for the treatment of aortic
stenosis (AS). Cerebrovascular events that occur during TAVR are a
well known risk which is associated with increased mortality. The vast
majority of neurological events in TAVR occur in the peri-procedural period [2] and are thought to be related to cerebral embolization and hypoperfusion [3]. Studies suggest that the highest rate of embolism
during TAVR is during valve positioning and deployment, and the second highest rate of embolism is during balloon aortic valvuloplasty
[3]. Embolic protection devices (EPDs) were developed to help reduce
⁎ Corresponding author at: 2799 W. Grand Blvd Detroit, MI 48202, United States of
Amercia.
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the risk of cerebrovascular events during transcatheter procedures. In
TAVR, the use of an FDA approved cerebral protection device (Sentinel
CPS®, Boston Scientiﬁc, Marlborough, MA, USA) has demonstrated reduced cerebral lesions as assessed with magnetic resonance imaging
(MRI) [4]. When performing TAVR with ﬁlter-based cerebral embolic
protection (CEP) devices, embolic debris is captured in 90% to 95% of patients [5].
The lessons of TAVR can provide valuable insights and developments
for other left sided cardiac procedures. The concept of trapping debris
and preventing distal embolization is an intuitively appealing concept
for other high risk procedures such as transcatheter mitral valve therapies as well as other procedures with high risk for cerebrovascular
involvement.
We hereby report on our experience on the safety and efﬁcacy of
using embolic protection devices in a patient population undergoing
transcatheter procedures felt to be at high risk for cerebrovascular embolic events.
2. Methods
A single-center, retrospective, observational study was performed
with IRB approval. We identiﬁed 33 patients felt to be at high risk for
cerebroembolic events. In which EPD was felt to be indicated to reduce
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whether or not Sentinel is associated with reduction in clinical
endpoints.

peri-procedural stroke risk. High risk features identiﬁed included high
atheroma burden in the aortic arch, left sided valve vegetations, intracardiac thrombi and severe left sided valve calciﬁcations/thrombi.

5. Limitations
3. Results

This is a retrospective analysis and carries the risk of confounding.
The lack of a control group is also a limitation. The decision to use CEP
in these cases was entirely based on physicians qualitative estimation
of stroke risk, which could be biased.

Average CHA2DS2VASC score was 5.2 ± 1.2 (indicating elevated
peri-procedural stroke risk even in patients without atrial ﬁbrillation
[6]), average age was 73.8 years, 36.7% females, and 30% with history
of a prior stroke. CEP with Sentinel™ CPSV® cerebral protection device
was used in all patients. Patients' selection to receive a Sentinel cerebral
protection device was based on clinical judgment regarding high risk of
peri-procedural embolism, see Table 1. The procedures were performed
according to the CEP instructions for use. All patients had available CT
angiogram that was used to identify high-risk features that may preclude the use of the CEP device. CT planning for Sentinel is key in
identiﬁying the size of the vessels (recommended vessel size of
9–15 mm for the right brachio-cephalic and 6.5–10 mm for the left carotid), anatomy of the neck vessels (whether a favorable angle, bovine
arch or how much calcium) and potential stenosis. Throughout the procedure, unfractionated heparin was administered to maintain an activated clotting time > 250 s. After the transcatheter procedure, the
ﬁlters were removed and their content underwent clinical examination.
All patients had successful placement of embolic protection device
without procedural complications or difﬁculties. No patients developed
periprocedural stroke or vascular complications.

6. Conclusion and summary
High-risk catheter-based vascular and structural interventions carry
signiﬁcant risk of stroke related presumably to embolization of atheroma, vegetation or thrombus. In TAVR, the use of a cerebral protection
device (Sentinel CPS®) has been proven to reduce cerebral lesions as
assessed with magnetic resonance imaging (MRI). We hereby report a
30 patient single-center study where we used Sentinel for non-TAVR indications in selected high-risk individuals undergoing a variety of vascular and structural procedures.
Overall, the use of Sentinel for non-TAVR indications appears feasible and safe. We had no strokes in our 30-patient series. The use of cerebral protection devices should be studied further in non-TAVR
patients to establish its role and its beneﬁts, especially with expanding
the number of non-TAVR transcatheter interventions.
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Due to the elevated risk of stroke in endo-vascular procedures, multiple EPDs were developed to help reduce this risk. In TAVR, the use of
the FDA approved Sentinel has demonstrated reduced cerebral lesions
as assessed with magnetic resonance imaging (MRI) [4] but is yet to
show a clinical reduction in cerebro-vascular events. An ongoing trial
is being performed to answer this very important question [PROTECTED
TAVR trial (NCT04149535)]. Data for the use of EPDs is non-TAVR procedures is scarce and outcomes are not known. Recently, a multi-center
European study demonstrated the efﬁcacy and safety of using Sentinel
in patients presenting with left atrial appendage thomrbus who are
treated with trans-catheter left atrial appendage closure while using
the Sentinel device [7]. Our paper adds to the growing nonrandomized literature about the use of Sentinel for non-TAVR applications. More studies are needed to inform clinical practice and to

Table 1
Rationale for use of cerebral embolic protection in non-TAVR procedures.
Procedure performed

Cases
(%)

Rational for CEP use

Transcatheter mitral valve
replacement
Percutaneous balloon mitral
valvuloplasty
Percutaneous coronary
intervention (with or
without Impella)
Balloon aortic valvuloplasty
Thrombus aspiration with
Angiovac system
Diagnostic coronary
angiogram
Patent Foramen Ovale closure

30.3
21.2

• Highly calciﬁed valve leaﬂets
• Concern for valve thrombus
• Heavily calciﬁed leaﬂets

18.2

• Large atheroma burden in aortic arch

12.1
6.1

•
•
•
•
•
•

Transcatheter edge-to-edge
repair with MitraClip
system

6.1
3

3
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Heavily calciﬁed valve leaﬂets
Thrombus in transit
Large thrombus in aortic arch
Large aortic arch thrombus
Aortic valve vegetations
Deep venous thrombus with right to
left shunt through PFO and concern for
thrombus in transit
• Deep venous thrombus with bidirectional shunt through PFO and concern
for thrombus in transit
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